Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 33, Issue 6, 2009, Pages 1022-1031

  Hough, David ^a   Lindenmayer, Jean Pierre ^b   Gopal, Srihari ^a   Melkote, Rama ^a   Lim, Pilar ^a   Herben, Virginie ^c   Yuen, Eric ^a   Eerdekens, Marielle ^c  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Atypical antipsychotic; Deltoid injection; Gluteal injection; Paliperidone palmitate; Schizophrenia; Tolerability

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CONSTA; NEUROLEPTIC AGENT; PALIPERIDONE; PALIPERIDONE PALMITATE; RISPERIDONE; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGITATION; AKATHISIA; ANGINA PECTORIS; ANXIETY DISORDER; ARTICLE; AUTOMUTILATION; BODY WEIGHT; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DELTOID MUSCLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GALACTORRHEA; GEOGRAPHIC DISTRIBUTION; GLUCOSE BLOOD LEVEL; GLUTEUS MAXIMUS MUSCLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; INCIDENCE; INJECTION SITE PAIN; INSOMNIA; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; NEUROLEPTIC MALIGNANT SYNDROME; OUTPATIENT DEPARTMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PROLACTIN BLOOD LEVEL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHIZOPHRENIA; SEX RATIO; SIDE EFFECT; STEADY STATE; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; TACHYCARDIA; TARDIVE DYSKINESIA; TORSADE DES POINTES; TREMOR; VITAL SIGN; WEIGHT;

ADULT; BUTTOCKS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERNATIONALITY; ISOXAZOLES; MALE; MIDDLE AGED; MUSCLE, SKELETAL; PYRIMIDINES; SCHIZOPHRENIA; SHOULDER; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 67749084103     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.05.014     Document Type: Article

References (20)

1. Agresti A., and Min Y. Simple improved confidence intervals for comparing matched proportions. Stat Med 24 (2005) 729-740
2. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156 (1999) 1686-1696
3. Barnes T.R. A rating scale for drug-induced akathisia. Br J Psychiatry 154 (1989) 672-676
4. Barnes T.R., and Curson D.A. Long-term depot antipsychotics. A risk-benefit assessment. Drug Safety 10 (1994) 464-479
5. Cleton A., Rossenu S., Hough D., Crauwels H., Berwaerts J., Gopal S., et al. Assessment of the dose proportionality of paliperidone palmitate 25, 50, 100 and 150 mg eq., a new long-acting injectable antipsychotic following administration in the deltoid or gluteal muscles. Clin Pharmacol Ther 83 (2008) S31
6. Guy W. AIMS. Abnormal Involuntary Movement Scale, Early Clinical Drug Evaluation Unit (ECDEU), Assessment Manual for Psychopharmacology. In: Rockville M.D. (Ed). Nat Inst Ment Health 338 (1976) 534-537
7. Hough D., Gopal S., Vijapurkar U., Pilar L., Morozova M., and Eerdekens M. Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Abstracts of the 63 rd annual scientific convention and meeting of the Society of Biological Psychiatry, Washington, DC, USA. Biol Psychiatry 63 Suppl 7 (2008) 1 S-319 S
8. Kane J.M. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry 64 Suppl 16 (2003) 34-40
9. Kane J.M., Aguglia E., Altamura A.C., Ayuso Gutierrez J.L., Brunello N., Fleischhacker W.W., et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 8 (1998) 55-66
10. Kane J.M., Canas F., Kramer M., Ford L., Gassmann-Mayer C., Lim P., et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 90 (2007) 147-161
11. Keith S.J., Pani L., Nick B., Emsley R., San L., Turner M., et al. Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatr Serv 55 (2004) 997-1005
12. Kramer M., Simpson G., Maciulis V., Kushner S., Vijapurkar U., Lim P., et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 27 (2007) 6-14
13. Kramer, M., Litman, R., Hough, D., Lane, R., Pilar, L., Liu, Y., et al., . Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. (Submitted for publication)
14. Marder S.R., Kramer M., Ford L., Eerdekens E., Lim P., Eerdekens M., et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 62 12 (2007) 1363-1370
15. Nasrallah H.A. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 115 (2007) 260-267
16. Nasrallah, H.A., Gopal, S., Gassmann-Mayer, C., Quiroz, J.A., Lim, P., Eerdekens, M., et al. A controlled, evidence-based trial of paliperidone palmitate, an investigational long-acting injectable antipsychotic, in schizophrenia (Submitted for publication).
17. Pandina, G., Lindenmayer, J., Lull, J., Lim, P., Gopal, S., Herben, V., et al. A randomized, placebo-controlled study to assess the efficacy and safety of three doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. (Submitted for publication)
18. Simpson G.M., and Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212 (1970) 11-19
19. Spina E., and Cavallaro R. The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia. Expert Opin Drug Saf 6 (2007) 651-662
20. Thyssen A., Ning X., Herben V., Rusch S., Kushner S., Kusumakar V., et al. Pharmacokinetics of long-acting injectable risperidone injected in deltoid muscle compared to gluteal muscle injection in subjects with schizophrenia. American Psychiatric Association 161st Annual Meeting Program Book (2008) 160 Abst. no: NR4-003